Approval · Notice of Compliance 25933 · 2021
COSENTYX: Notice of Compliance 25933
Issued May 26, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25933
- Date
- May 26, 2021
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New Indication: COSENTYX is indicated for the treatment of active nonradiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| COSENTYX | Not yet assigned | — |
Medicinal ingredients
- SECUKINUMAB 150 MG per ML
- SECUKINUMAB 150 MG per VIAL